JAK2 Gene, V617F Mutation, Qualitative (INACTIVE as of 08/16/21: Refer to 3004046 in the August Hotline)
Aids in the workup of suspected myeloproliferative neoplasms. Detects the JAK2 V617F mutation in peripheral blood or bone marrow.
Polymerase Chain Reaction
DNA isolation: Sun-Sat
Assay: Sun, Tue-Fri
New York DOH Approval Status
Lavender (EDTA) OR bone marrow (EDTA). Also acceptable: DNA extracted by CLIA
Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Do not freeze. Transport 3 mL bone marrow. (Min: 1 mL)
Extracted DNA: Transport 40 uL DNA with at least 50 ng/uL concentration. (Min: 40 uL) Transport DNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Plasma, serum, FFPE tissue blocks/slides, or frozen tissue, DNA extracted by a non-CLIA lab. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
Extracted DNA: Ambient: 1 month; Refrigerate: Indefinitely; Frozen: Indefinitely
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0051245||JAK2 Gene, V617F Mutation, Qualitative||43399-5|
- BCR-ABL1 negative tesing
- MPN JAK 2
- Tyrosine Kinase Mutation